Medical - Devices
Compare Stocks
5 / 10Stock Comparison
INMD vs STAA vs LNTH vs NVCR vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Drug Manufacturers - Specialty & Generic
Medical - Instruments & Supplies
Medical - Instruments & Supplies
INMD vs STAA vs LNTH vs NVCR vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Drug Manufacturers - Specialty & Generic | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $882M | $1.35B | $5.92B | $1.92B | $161.07B |
| Revenue (TTM) | $375M | $239M | $1.55B | $674M | $10.58B |
| Net Income (TTM) | $87M | $-80M | $279M | $-173M | $2.98B |
| Gross Margin | 77.8% | 75.6% | 60.5% | 75.2% | 66.3% |
| Operating Margin | 21.3% | -33.3% | 18.8% | -27.2% | 30.5% |
| Forward P/E | 9.6x | 70.2x | 17.5x | — | 43.8x |
| Total Debt | $13M | $38M | $738K | $290M | $303M |
| Cash & Equiv. | $303M | $153M | $359M | $103M | $3.37B |
INMD vs STAA vs LNTH vs NVCR vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| InMode Ltd. (INMD) | 100 | 95.0 | -5.0% |
| STAAR Surgical Comp… (STAA) | 100 | 70.3 | -29.7% |
| Lantheus Holdings, … (LNTH) | 100 | 662.8 | +562.8% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INMD vs STAA vs LNTH vs NVCR vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INMD is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.97 vs ISRG's 2.01
- Lower P/E (9.6x vs 43.8x), PEG 0.97 vs 2.01
STAA ranks third and is worth considering specifically for defensive.
- Beta 0.54, current ratio 4.55x
- +40.3% vs ISRG's -15.4%
LNTH is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 0.47
- 41.9% 10Y total return vs ISRG's 5.5%
- Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
- Beta 0.47 vs NVCR's 2.20, lower leverage
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
ISRG carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 20.5% revenue growth vs STAA's -23.7%
- 28.2% margin vs STAA's -33.6%
- 14.8% ROA vs STAA's -17.8%, ROIC 15.0% vs -13.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs STAA's -23.7% | |
| Value | Lower P/E (9.6x vs 43.8x), PEG 0.97 vs 2.01 | |
| Quality / Margins | 28.2% margin vs STAA's -33.6% | |
| Stability / Safety | Beta 0.47 vs NVCR's 2.20, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +40.3% vs ISRG's -15.4% | |
| Efficiency (ROA) | 14.8% ROA vs STAA's -17.8%, ROIC 15.0% vs -13.2% |
INMD vs STAA vs LNTH vs NVCR vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
INMD vs STAA vs LNTH vs NVCR vs ISRG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LNTH leads in 3 of 6 categories
ISRG leads 1 • INMD leads 1 • STAA leads 0 • NVCR leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 44.2x STAA's $239M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to STAA's -33.6%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $375M | $239M | $1.5B | $674M | $10.6B |
| EBITDAEarnings before interest/tax | $81M | -$71M | $347M | -$165M | $3.8B |
| Net IncomeAfter-tax profit | $87M | -$80M | $279M | -$173M | $3.0B |
| Free Cash FlowCash after capex | $91M | -$34M | $372M | -$48M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +77.8% | +75.6% | +60.5% | +75.2% | +66.3% |
| Operating MarginEBIT ÷ Revenue | +21.3% | -33.3% | +18.8% | -27.2% | +30.5% |
| Net MarginNet income ÷ Revenue | +23.3% | -33.6% | +18.0% | -25.7% | +28.2% |
| FCF MarginFCF ÷ Revenue | +24.2% | -14.4% | +24.0% | -7.1% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.3% | +18.1% | +1.2% | +12.3% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -30.8% | +47.8% | +76.5% | -100.0% | +18.8% |
Valuation Metrics
INMD leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 9.7x trailing earnings, INMD trades at a 83% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), INMD offers better value at 0.98x vs ISRG's 2.65x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $882M | $1.3B | $5.9B | $1.9B | $161.1B |
| Enterprise ValueMkt cap + debt − cash | $593M | $1.2B | $5.6B | $2.1B | $158.0B |
| Trailing P/EPrice ÷ TTM EPS | 9.73x | -16.84x | 26.69x | -13.80x | 57.62x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.64x | 70.16x | 17.52x | — | 43.84x |
| PEG RatioP/E ÷ EPS growth rate | 0.98x | — | — | — | 2.65x |
| EV / EBITDAEnterprise value multiple | 6.88x | — | 14.61x | — | 43.62x |
| Price / SalesMarket cap ÷ Revenue | 2.38x | 5.63x | 3.84x | 2.92x | 16.00x |
| Price / BookPrice ÷ Book value/share | 1.33x | 3.93x | 5.72x | 5.51x | 9.17x |
| Price / FCFMarket cap ÷ FCF | 10.46x | — | 16.73x | — | 64.67x |
Profitability & Efficiency
LNTH leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-51 for NVCR. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs STAA's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +13.3% | -23.2% | +24.3% | -50.8% | +16.9% |
| ROA (TTM)Return on assets | +11.8% | -17.8% | +12.4% | -16.5% | +14.8% |
| ROICReturn on invested capital | +13.5% | -13.2% | +30.6% | -16.4% | +15.0% |
| ROCEReturn on capital employed | +12.1% | -11.2% | +17.1% | -28.9% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 | 5 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.02x | 0.11x | 0.00x | 0.85x | 0.02x |
| Net DebtTotal debt minus cash | -$289M | -$115M | -$358M | $187M | -$3.1B |
| Cash & Equiv.Liquid assets | $303M | $153M | $359M | $103M | $3.4B |
| Total DebtShort + long-term debt | $13M | $38M | $738,000 | $290M | $303M |
| Interest CoverageEBIT ÷ Interest expense | — | — | 11.72x | -96.80x | — |
Total Returns (Dividends Reinvested)
LNTH leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, STAA leads with a +40.3% total return vs ISRG's -15.4%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -5.9% | +15.6% | +35.3% | +28.3% | -19.3% |
| 1-Year ReturnPast 12 months | -2.1% | +40.3% | +13.1% | +1.1% | -15.4% |
| 3-Year ReturnCumulative with dividends | -60.2% | -59.7% | -4.0% | -75.7% | +49.6% |
| 5-Year ReturnCumulative with dividends | -63.9% | -80.2% | +314.2% | -91.3% | +58.7% |
| 10-Year ReturnCumulative with dividends | +105.0% | +273.7% | +4192.5% | +30.3% | +554.2% |
| CAGR (3Y)Annualised 3-year return | -26.4% | -26.1% | -1.4% | -37.6% | +14.4% |
Risk & Volatility
LNTH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LNTH is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs ISRG's 75.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 0.54x | 0.47x | 2.20x | 1.02x |
| 52-Week HighHighest price in past year | $16.74 | $30.81 | $93.00 | $20.06 | $603.88 |
| 52-Week LowLowest price in past year | $12.72 | $15.64 | $47.25 | $9.82 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +83.2% | +88.5% | +97.8% | +83.9% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 39.8 | 70.0 | 61.2 | 69.8 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 804K | 1.2M | 886K | 1.5M | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: INMD as "Buy", STAA as "Hold", LNTH as "Buy", NVCR as "Buy", ISRG as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -15.9% for STAA (target: $23).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $16.00 | $22.95 | $101.00 | $33.50 | $622.60 |
| # AnalystsCovering analysts | 11 | 15 | 17 | 15 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +14.5% | +0.5% | +5.1% | 0.0% | +1.4% |
LNTH leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). ISRG leads in 1 (Income & Cash Flow).
INMD vs STAA vs LNTH vs NVCR vs ISRG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INMD or STAA or LNTH or NVCR or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -23. 7% for STAAR Surgical Company (STAA). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate InMode Ltd. (INMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INMD or STAA or LNTH or NVCR or ISRG?
On trailing P/E, InMode Ltd.
(INMD) is the cheapest at 9. 7x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, InMode Ltd. is actually cheaper at 9. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: InMode Ltd. wins at 0. 97x versus Intuitive Surgical, Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — INMD or STAA or LNTH or NVCR or ISRG?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +314. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INMD or STAA or LNTH or NVCR or ISRG?
By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.
(LNTH) is the lower-risk stock at 0. 47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 370% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — INMD or STAA or LNTH or NVCR or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -23. 7% for STAAR Surgical Company (STAA). On earnings-per-share growth, the picture is similar: Intuitive Surgical, Inc. grew EPS 22. 6% year-over-year, compared to -295. 1% for STAAR Surgical Company. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INMD or STAA or LNTH or NVCR or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -33. 6% for STAAR Surgical Company — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INMD or STAA or LNTH or NVCR or ISRG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, InMode Ltd. (INMD) is the more undervalued stock at a PEG of 0. 97x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, InMode Ltd. (INMD) trades at 9. 6x forward P/E versus 70. 2x for STAAR Surgical Company — 60. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — INMD or STAA or LNTH or NVCR or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is INMD or STAA or LNTH or NVCR or ISRG better for a retirement portfolio?
For long-horizon retirement investors, STAAR Surgical Company (STAA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
54), +273. 7% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STAA: +273. 7%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INMD and STAA and LNTH and NVCR and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INMD is a small-cap deep-value stock; STAA is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.